Please provide your email address to receive an email when new articles are posted on . “Elevated [IOP] is one of the major risk factors for development and progression of POAG [primary open-angle ...

Please provide your email address to receive an email when new articles are posted on . Combined cataract surgery with iStent inject significantly reduced medication burden in patients with glaucoma.

WILMINGTON, NC (WECT) - A procedure for those with Glaucoma is making it easier to manage the degenerative eye condition on a day-to-day basis. Health officials say glaucoma is the second leading ...

Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy & Safety Across the Entire Glaucoma Disease Spectrum SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos ...

While Both iStent and iStent inject Showed Significant IOP and Medication Reduction in Combo-Cataract Procedures at 1 Year Postoperative, iStent inject Achieved Greater Absolute IOP Declines with 93% ...

Robert Haverly, MD, of Saint Vincent Surgery Center in Erie, Pa., has incorporated the iStent into his practice for glaucoma treatment, according to an Erie Times-News report. The iStent was the ...

CHERRY HILL, N.J. (WPVI) -- A new procedure is helping to preserve vision for some people with glaucoma. Glaucoma is a silent thief, affecting 3 million Americans, slowly robbing them of their sight.

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos Corp. reported 12-month results from the pivotal IDE trial of its Istent Infinite trabecular micro-bypass system, showing substantial reduction in mean diurnal intraocular pressure (IOP) in ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...